Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 15/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 13/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213973 | 0.91 | TBXA2R (0.43) | TBXA2RPTGDRPDE2ATSHRNPSR1 | |
| SCHEMBL176586 | 0.88 | CNR2 (0.45) | CNR2TSHR | |
| SCHEMBL176830 | 0.87 | HPGD (0.46) | CNR2TSHR | |
| SCHEMBL176986 | 0.85 | CNR2 (0.47) | CNR2 | |
| SCHEMBL176616 | 0.85 | CNR2 (0.47) | CNR2 | |
| SCHEMBL3469170 | 0.85 | CNR2 (0.47) | CNR2 | |
| SCHEMBL3466374 | 0.84 | CNR2 (0.46) | CNR2 | |
| SCHEMBL3466388 | 0.80 | CNR2 (0.43) | CNR2 | |
| SCHEMBL257729 | 0.80 | CNR1 (0.39) | CNR2TBXA2RPTGDRPDE2ATSHR | |
| SCHEMBL176633 | 0.78 | CNR2 (0.42) | CNR2TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378117-B2 | 1-(4-fluoro-phenyl)-8-(4-methyl-benzyl)-1,4,5,6,7,8-hexahydro-cycloheptapyrazole-3-carboxylic acid (1,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amide; antidepressant, anxiolytic; nervous system disorders, metabolic disorders, obesity | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070968-A1 | Hexahydro-Cycloheptapyrazole Cannabinoid Modulators | CNR2, CNR1, FAAH | CNR2 1/4885PTGER4 568/4885TBXA2R 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.